Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
186 Results for "
ephrin,
" in MedChemExpress (MCE) Product Catalog:
Products (186)
186 Results for "ephrin," in MCE Product Catalog:
1
Target:
Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt
Research Areas:
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
1
1 Cited Publications
Cat. No.: HY-P73017
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EFNB2; Eph-Related Receptor Tyrosine Kinase Ligand 5; Prev. EPLG5; MGC126226; Ephrin-B2; MGC126227; LERK5; MGC126228; HTKL; EPH-Related Receptor Tyrosine Kinase Ligand 5; HTK Ligand; LERK-5; Htk-L; HTK-L; Ephrin B2; Ligand Of Eph-Related Kinase 5
1
1 Cited Publications
Cat. No.: HY-P72662
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: EFNA1; GMAN; Prev. TNFAIP4; Tumor Necrosis Factor Alpha-Induced Protein 4; Prev. EPLG1; TNF Alpha-Induced Protein 4; EPH-Related Receptor Tyrosine Kinase Ligand 1; LERK-1; Ephrin-A1; Tumor Necrosis Factor, Alpha-Induced Protein 4; LERK1; Epididymis Secret
1
1 Cited Publications
Cat. No.: HY-P75236
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EPHB2; Ephrin Type-B Receptor 2 Variant; Prev. EPHT3; Protein-Tyrosine Kinase HEK5; Prev. DRT; Elk-Related Tyrosine Kinase; Prev. ERK; ELK-Related Tyrosine Kinase; Tyrosine-Protein Kinase Receptor EPH-3; Eph Tyrosine Kinase 3; Ephrin Type-B Receptor 2; EP
1
1 Cited Publications
Cat. No.: HY-P70336
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EPHA2; Protein Tyrosine Kinase; Prev. ECK; CTRCT6; Tyrosine-Protein Kinase Receptor ECK; EphA2; Ephrin Type-A Receptor 2; ARCC2; Epithelial Cell Receptor Protein Tyrosine Kinase; CTPP1; Receptor Protein-Tyrosine Kinase; CTPA; EPH Receptor A2; Epithelial C
1
1 Cited Publications
Cat. No.: HY-P75748
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EPHB1; ELK; Prev. EPHT2; EK6; Hek6; Receptor Protein-Tyrosine Kinase; Neuronally-Expressed EPH-Related Tyrosine Kinase; Eph Tyrosine Kinase 2; Tyrosine-Protein Kinase Receptor EPH-2; EPH Tyrosine Kinase 2; Ephrin Type-B Receptor 1; EphB1; EPH-Like Kinase
Cat. No.: HY-18832
CAS No.: 1135205-94-5
Target:
Research Areas:
AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf .
Target:
Research Areas:
UniPR129 is a potent and orally active Eph/ephrin antagonist. UniPR129 can inhibit EphA2-ephrin-A1 interaction with an IC50 of 945 nM and a Ki of 370 nM. UniPR129 can inhibit angiogenesis and show antitumor and neuroprotective effect. UniPR129 can be used for the researches of cancer and neurological disease, such as colorectal cancer and optic neuropathy .
Target:
Research Areas:
UniPR1331 is an orally active 3β-hydroxy-Δ5-choline acid derivative that inhibits Eph-ephrin interactions. UniPR1331 blocks the interaction of VEGFR2 with its natural ligand vascular endothelial growth factor and inhibits subsequent autophosphorylation, signaling, and pro-angiogenic activation of endothelial cells. UniPR1331 exhibits anti-angiogenesis, anti-cancer and anti-inflammation effects. UniPR1331 can be used for the researches of cancer and inflammation, such as glioma and colitis .
Synonyms: 3,4,8,9-Tetrahydroxy urolithin
Target:
Cat. No.: HY-169849
CAS No.: 1428095-28-6
Target:
Research Areas:
EphA2 antagonist 1 (4b) is a bile acid conjugate and an ephrin type-A receptor 2 (EPHA2) inhibitor .
Cat. No.: HY-W078239
CAS No.: 313701-92-7
Target:
Research Areas:
EPHA4 antagonist-1 (Compound 2) is an EphA4 receptor antagonist. EPHA4 antagonist-1 is also an EphA2 receptor antagonist. EPHA4 antagonist-1 inhibits ephrin-A5 AP binding to EphA4 Fc receptor, with an IC50 of 10 μM .
Cat. No.: HY-P11035
Target:
Research Areas:
Cat. No.: HY-P3755
CAS No.: 532441-10-4
Cat. No.: HY-163835
Target:
Research Areas:
UniPR1454 targets EphA2 receptor, inhibits the EphA2-ephrin A1 interaction with an IC50 of 2.6 μM. UniPR1454 inhibits the proliferation of glioblastoma cell U251 .
Target:
Research Areas:
UniPR1447 is Dual EphA2 and EphB2 antagonist, with an IC50 of 6.6 μM for EphA2−ephrin-A1 binding .
Cat. No.: HY-171175
CAS No.: 2085767-98-0
Target:
Research Areas:
UniPR500, a UniPR129 derivative, is a competitive EphA2 receptor antagonist with a Ki of 0.78 μM. UniPR500 dose-dependently reduces binding of biotinylated ephrin-A1 to EphA2 with an IC50 value of 1.1 μM .
Cat. No.: HY-14575
CAS No.: 343326-69-2
Synonyms: Z-360 hemicalcium
Target:
Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt
Research Areas:
Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain .
Cat. No.: HY-133178R
CAS No.: 131086-98-1
Synonyms: 3,4,8,9-Tetrahydroxy urolithin (Standard)
Category:
Target:
Cat. No.: HY-17617R
CAS No.: 209219-38-5
Synonyms: Z-360 (Standard)
Target:
Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt Reference Standards
Research Areas:
Nastorazepide (Standard) is the analytical standard of Nastorazepide. This product is intended for research and analytical applications. Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
